Hemoglobin Testing Market Share, Global Size, Growth Analysis, and Forecast 2025-2033

Rahul Pal
Nov 12, 2025
4 min read

The global Hemoglobin Testing Market size was valued at USD 2.55 Billion in 2024. It is forecasted to reach USD 4.12 Billion by 2033, growing at a CAGR of 5.22% during the 2025-2033 period. Growth is driven by increasing chronic conditions such as diabetes and anemia, along with advancements in healthcare technology and expanding healthcare access worldwide.

Study Assumption Years

Base Year: 2024
Historical Year/Period: 2019-2024
Forecast Year/Period: 2025-2033

Hemoglobin Testing Market Key Takeaways

Current Market Size (2024): USD 2.55 Billion
CAGR: 5.22%
Forecast Period: 2025-2033
Major market drivers include improving healthcare systems, growing expenditure on medical services, increased awareness of blood-related illnesses, and technological advancements.
Rising home-based testing trends are fueling demand, reflecting a shift toward patient-centered care.
North America dominates the market due to advanced medical infrastructure and high prevalence of relevant diseases.
Challenges include the high cost of modern testing devices, though investments in economical point-of-care equipment present growth opportunities.

Sample Request Link: https://www.imarcgroup.com/hemoglobin-testing-market/requestsample

Market Growth Factors

The hemoglobin testing market has several key growth factors behind it. One factor is the global improvement of healthcare systems that makes available diagnostic testing and treatment on a larger scale. Due to higher healthcare spending, more frequent use of advanced medical tests is possible. Public knowledge of blood diseases such as anemia and diabetes is on the rise which calls for regular hemoglobin monitoring which in turn results in increased demand for the market. Moreover, technology improvements are still here and they are still making the tests more accurate and easier to use, thus making more people accept and use the tests.

Another important trend in the market is the increasing use of home and point-of-care testing for hemoglobin. This patient-friendly practice brings along the advantages of fast results and convenience when compared to the old-fashioned lab tests. For example, there are now portable analyzers that deliver fully tested results in just 60 seconds and thereby improve patient care and decision-making speed. This change is consistent with the general healthcare trends that put a premium on prolonged monitoring and self-care.

On top of that, AI (artificial intelligence) has been integrated into the industry which has resulted in the reformation of the diagnostics of hemoglobin by increasing the accuracy of results and efficiency of operations. Automated AI solutions are capable of quickly analyzing large data sets thus minimizing the chance of human error. There are alliances that connect research institutions and hospitals in addressing health care issues in the underserved population through the implementation of AI-based anemia screening. Such progress, along with the government-sponsored education campaigns on anemia screening for vulnerable groups of pregnant women and children, is a stronghold for market growth.

Market Segmentation

Product Type:
Reagents and Consumables: Includes test strips and disposables widely used across diagnostic applications.
Equipment: Constitutes analyzers and point-of-care devices; experiencing growth due to portability and technical advancement.
Technology:
Chromatography: Used for detailed hemoglobin variant analysis primarily in laboratories demanding precision.
Immunoassay: Popular for its speed and cost-effectiveness, favored in point-of-care and routine monitoring.
Others: Encompasses other technologies contributing to market dynamics.
End-User:
Laboratories: Hold a substantial share due to capacity for high-volume and extensive testing.
Hospitals: Provide critical patient diagnostic and monitoring services.
Research Centers: Drive innovation by developing new testing methods and technologies.
Region:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Regional Insights

North America leads the hemoglobin testing market, driven by its well-established healthcare infrastructure, high healthcare spending, and extensive preventive care awareness. The region benefits from rapid adoption of advanced diagnostic technologies and hosts many leading market players. This dominant positioning fosters significant market growth and innovation within the segment.

Recent Developments & News

August 2024: IIT Kharagpur collaborated with Sathya Sai Hospital to develop AI-powered anemia screening solutions targeting underprivileged populations.
June 2024: Horiba launched compact hematology analyzers (Yumizen H550E, H500E CT, and H500E OT) capable of combined CBC/DIFF with ESR testing from whole blood within 60 seconds.
February 2024: The Indian Academy of Pediatrics (IAP) initiated a nationwide campaign to raise awareness about anemia and key child health issues.

Key Players

Abbott Laboratories
Bio-Rad Laboratories
Danaher
EKF Diagnostics
F. Hoffmann-La Roche
Siemens Healthineers
Thermo Fisher Scientific
Alere
ACON Laboratories
ARKRAY
Bayer Medical Care
Daiichi Biotech
DiaSys Diagnostic Systems
Epinex Diagnostics
Erba Diagnostics

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302